NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer's disease

Current Neuropharmacology

Volumn 10, Issue 3, 2012, Pages 272-285

  Huang, Yu Jhen ^a,b   Lin, Chieh Hsin ^a,c   Lane, Hsien Yuan ^a,b   Tsai, Guochuan E ^d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

D serine; Glycine transporter; Memantine; Sarcosine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOSERINE; DEXTRO SERINE; DIZOCILPINE; DONEPEZIL; GALANTAMINE; HALOPERIDOL; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TARCRINE; UNCLASSIFIED DRUG;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL FEATURE; COGNITION; DELUSION; DEMENTIA; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; MEMORY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW;

EID: 84867521251     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912803217288     Document Type: Review

References (222)

1. Thies, W.; Bleiler, L. Alzheimer's disease facts and figures. Alzheimer's & dementia: J. Alzheimer's Ass., 2011, 7 (2), 208-44.
2. Fratiglioni, L.; De Ronchi, D.; Aguero-Torres, H. Worldwide prevalence and incidence of dementia. Drugs Aging, 1999, 15 (5), 365-75.
3. Ritchie, K.; Kildea, D. Is senile dementia age-related or ageing related?--evidence from meta-analysis of dementia prevalence in the oldest old. Lancet, 1995, 346 (8980), 931-4.
4. Ferri, C. P.; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y., Global prevalence of dementia: a Delphi consensus study. Lancet, 2005, 366 (9503), 2112-2117.
5. Brodaty, H.; Breteler, M. M.; Dekosky, S. T.; Dorenlot, P.; Fratiglioni, L.; Hock, C.; Kenigsberg, P. A.; Scheltens, P.; De Strooper, B. The world of dementia beyond 2020. J. Am. Geriatr. Soc., 2011, 59 (5), 923-7.
6. Lipton, S. A.; Rosenberg, P. A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330 (9), 613-22.
7. Farber, N. B.; Newcomer, J. W.; Olney, J. W. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog. Brain Res., 1998, 116, 421-37.
8. Silva, A. J. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J. Neurobiol., 2003, 54 (1), 224-37.
9. Matynia, A.; Kushner, S. A.; Silva, A. J., Genetic approaches to molecular and cellular cognition: a focus on LTP and learning and memory. Annu. Rev. Genet., 2002, 36, 687-720.
10. Ye, X.; Carew, T. J. Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins. Neuron, 2010, 68 (3), 340-61.
11. Kalia, L. V.; Kalia, S. K.; Salter, M. W. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol., 2008, 7 (8), 742-755.
12. Hynd, M. R.; Scott, H. L.; Dodd, P. R. Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J. Neurochem. 2004, 90 (4), 913-9.
13. Benarroch, E. E. NMDA receptors: recent insights and clinical correlations. Neurology 2011, 76 (20), 1750-7.
14. Lau, C. G.; Zukin, R. S., NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 2007, 8 (6), 413-26.
15. Grosshans, D. R.; Clayton, D. A.; Coultrap, S. J.; Browning, M. D. LTP leads to rapid surface expression of NMDA but not AMPA receptors in adult rat CA1. Nat. Neurosci., 2002, 5 (1), 27-33.
16. Montgomery, J. M.; Selcher, J. C.; Hanson, J. E.; Madison, D. V., Dynamin-dependent NMDAR endocytosis during LTD and its dependence on synaptic state. BMC Neurosci., 2005, 6, 48.
17. Chen, P.; Gu, Z.; Liu, W.; Yan, Z. Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol. Pharmacol. 2007, 72 (1), 40-51.
18. Zhao, M. G.; Toyoda, H.; Lee, Y. S.; Wu, L. J.; Ko, S. W.; Zhang, X. H.; Jia, Y.; Shum, F.; Xu, H.; Li, B. M.; Kaang, B. K.; Zhuo, M. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron, 2005, 47 (6), 859-72.
19. Nakazawa, T.; Komai, S.; Watabe, A. M.; Kiyama, Y.; Fukaya, M.; Arima-Yoshida, F.; Horai, R.; Sudo, K.; Ebine, K.; Delawary, M.; Goto, J.; Umemori, H.; Tezuka, T.; Iwakura, Y.; Watanabe, M.; Yamamoto, T.; Manabe, T. NR2B tyrosine phosphorylation modulates fear learning as well as amygdaloid synaptic plasticity. EMBO J., 2006, 25 (12), 2867-77.
20. Gardoni, F.; Mauceri, D.; Malinverno, M.; Polli, F.; Costa, C.; Tozzi, A.; Siliquini, S.; Picconi, B.; Cattabeni, F.; Calabresi, P.; Di Luca, M. Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J. Neurosci., 2009, 29 (3), 669-77.
21. Tang, Y. P.; Shimizu, E.; Dube, G. R.; Rampon, C.; Kerchner, G. A.; Zhuo, M.; Liu, G.; Tsien, J. Z. Genetic enhancement of learning and memory in mice. Nature 1999, 401 (6748), 63-9.
22. Hawasli, A. H.; Benavides, D. R.; Nguyen, C.; Kansy, J. W.; Hayashi, K.; Chambon, P.; Greengard, P.; Powell, C. M.; Cooper, D. C.; Bibb, J. A. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci., 2007, 10 (7), 880-6.
23. Fradley, R. L.; O'Meara, G. F.; Newman, R. J.; Andrieux, A.; Job, D.; Reynolds, D. S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res., 2005, 163 (2), 257-64.
24. Brigman, J. L.; Wright, T.; Talani, G.; Prasad-Mulcare, S.; Jinde, S.; Seabold, G. K.; Mathur, P.; Davis, M. I.; Bock, R.; Gustin, R. M.; Colbran, R. J.; Alvarez, V. A.; Nakazawa, K.; Delpire, E.; Lovinger, D. M.; Holmes, A. Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. J. Neurosci., 2010, 30 (13), 4590-600.
25. Nakazawa, K.; Quirk, M. C.; Chitwood, R. A.; Watanabe, M.; Yeckel, M. F.; Sun, L. D.; Kato, A.; Carr, C. A.; Johnston, D.; Wilson, M. A.; Tonegawa, S. Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science, 2002, 297 (5579), 211-8.
26. Collingridge, G. L.; Bliss, T. V. Memories of NMDA receptors and LTP. Trends Neurosci., 1995, 18 (2), 54-6.
27. Olney, J. W.; Farber, N. B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry, 1995, 52 (12), 998-1007.
28. Lissek, S.; Gunturkun, O. Maintenance in working memory or response selection? Functions of NMDA receptors in the pigeon prefrontal cortex. Behav. Brain Res., 2004, 153 (2), 497-506.
29. Choi, D. W. Excitotoxic cell death. J. Neurobiol., 1992, 23 (9), 1261-76.
30. Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med., 2010, 362 (4), 329-44.
31. Parsons, C. G.; Stoffler, A.; Danysz, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology, 2007, 53 (6), 699-723.
32. Uhasz, G. J.; Barkoczi, B.; Vass, G.; Datki, Z.; Hunya, A.; Fulop, L.; Budai, D.; Penke, B.; Szegedi, V. Fibrillar Abeta (1-42) enhances NMDA receptor sensitivity via the integrin signaling pathway. J. Alzheimer's Dis., 2010, 19 (3), 1055-67.
33. Alberdi, E.; Sanchez-Gomez, M. V.; Cavaliere, F.; Perez-Samartin, A.; Zugaza, J. L.; Trullas, R.; Domercq, M.; Matute, C. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium, 2010, 47 (3), 264-72
34. Butterfield, D. A.; Pocernich, C. B. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs, 2003, 17 (9), 641-52.
35. Lesne, S.; Ali, C.; Gabriel, C.; Croci, N.; MacKenzie, E. T.; Glabe, C. G.; Plotkine, M.; Marchand-Verrecchia, C.; Vivien, D.; Buisson, A. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J. Neurosci., 2005, 25 (41), 9367-77.
36. Gordon-Krajcer, W.; Salinska, E.; Lazarewicz, J. W. N-methyl-daspartate receptor-mediated processing of beta-amyloid precursor protein in rat hippocampal slices: in vitro--superfusion study. Folia Neuropathol., 2002, 40 (1), 13-7.
37. Ando, K.; Uemura, K.; Kuzuya, A.; Maesako, M.; Asada-Utsugi, M.; Kubota, M.; Aoyagi, N.; Yoshioka, K.; Okawa, K.; Inoue, H.; Kawamata, J.; Shimohama, S.; Arai, T.; Takahashi, R.; Kinoshita, A. N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease. J. Biol. Chem., 2011, 286 (9), 7619-28.
38. Yamada, K.; Nabeshima, T. Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging. Microsc. Res. Tech., 1998, 43 (1), 68-74.
39. Ikonomidou, C.; Bosch, F.; Miksa, M.; Bittigau, P.; Vockler, J.; Dikranian, K.; Tenkova, T. I.; Stefovska, V.; Turski, L.; Olney, J. W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science, 1999, 283 (5398), 70-4.
40. Fiske, B. K.; Brunjes, P. C. NMDA receptor regulation of cell death in the rat olfactory bulb. J. Neurobiol., 2001, 47 (3), 223-32.
41. Ikonomidou, C.; Stefovska, V.; Turski, L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc. Natl. Acad. Sci. U. S. A., 2000, 97 (23), 12885-90.
42. Monti, B.; Contestabile, A. Blockade of the NMDA receptor increases developmental apoptotic elimination of granule neurons and activates caspases in the rat cerebellum. Eur. J. Neurosci., 2000, 12 (9), 3117-23.
43. Ikonomidou, C.; Bittigau, P.; Koch, C.; Genz, K.; Hoerster, F.; Felderhoff-Mueser, U.; Tenkova, T.; Dikranian, K.; Olney, J. W. Neurotransmitters and apoptosis in the developing brain. Biochem. Pharmacol., 2001, 62, 401-405.
44. Adams, S. M.; de Rivero Vaccari, J. C.; Corriveau, R. A. Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. J. Neurosci., 2004, 24 (42), 9441-50.
45. de Rivero Vaccari, J. C.; Casey, G. P.; Aleem, S.; Park, W. M.; Corriveau, R. A. NMDA receptors promote survival in somatosensory relay nuclei by inhibiting Bax-dependent developmental cell death. Proc. Natl. Acad. Sci. U. S. A., 2006, 103 (45), 16971-6.
46. 2+ deficiency. J. Neurochem., 2003, 85 (2), 525-33.
47. Hetman, M.; Kharebava, G. Survival signaling pathways activated by NMDA receptors. Curr. Top. Med. Chem., 2006, 6 (8), 787-99.
48. Hansen, H. H.; Briem, T.; Dzietko, M.; Sifringer, M.; Voss, A.; Rzeski, W.; Zdzisinska, B.; Thor, F.; Heumann, R.; Stepulak, A.; Bittigau, P.; Ikonomidou, C., Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol. Dis., 2004, 16 (2), 440-53.
49. Lei, G.; Xia, Y.; Johnson, K. M. The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neuro degeneration. Neuropsychopharmacology, 2008, 33 (6), 1343-53.
50. Olney, J. W.; Wozniak, D. F.; Farber, N. B. Excitotoxic Neuro degeneration in Alzheimer Disease: New Hypothesis and New Therapeutic Strategies. Arch. Neurol., 1997, 54, 1234-1240.
51. Wozniak, D. F.; Dikranian, K.; Ishimaru, M. J.; Nardi, A.; Corso, T. D.; Tenkova, T.; Olney, J. W.; Fix, A. S. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's Disease. Neurobiol. Dis., 1998, 5, 305-322.
52. Clayton, D. A.; Mesches, M. H.; Alvarez, E.; Bickford, P. C.; Browning, M. D. A hippocampal NR2B deficit can mimic age related changes in long-term potentiation and spatial learning in the Fischer 344 rat. J. Neurosci., 2002, 22 (9), 3628-37.
53. Ossowska, K.; Wolfarth, S.; Schulze, G.; Wardas, J.; Pietraszek, M.; Lorenc-Koci, E.; Smialowska, M.; Coper, H. Decline in motor functions in aging is related to the loss of NMDA receptors. Brain Res., 2001, 907 (1-2), 71-83.
54. Liu, P.; Smith, P. F.; Darlington, C. L. Glutamate receptor subunits expression in memory-associated brain structures: regional variations and effects of aging. Synapse, 2008, 62 (11), 834-41.
55. Kuehl-Kovarik, M. C.; Magnusson, K. R.; Premkumar, L. S.; Partin, K. M. Electrophysiological analysis of NMDA receptor subunit changes in the aging mouse cortex. Mech. Ageing Dev. 2000, 115 (1-2), 39-59.
56. Clayton, D. A.; Grosshans, D. R.; Browning, M. D. Aging and surface expression of hippocampal NMDA receptors. J. Biol. Chem., 2002, 277 (17), 14367-9.
57. Das, S. R.; Jensen, R.; Kelsay, R.; Shumaker, M.; Bochart, R.; Brim, B.; Zamzow, D.; Magnusson, K. R. Reducing expression of GluN1(0XX) subunit splice variants of the NMDA receptor interferes with spatial reference memory. Behav. Brain Res., 2012, 230 (2), 317-24.
58. Magnusson, K. R.; Brim, B. L.; Das, S. R. Selective vulnerabilities of N-methyl-D-aspartate (NMDA) receptors during brain aging. Frontiers Aging Neurosci., 2010, 2, 11.
59. Boric, K.; Munoz, P.; Gallagher, M.; Kirkwood, A. Potential adaptive function for altered long-term potentiation mechanisms in aging hippocampus. J. Neurosci., 2008, 28 (32), 8034-9.
60. Bodhinathan, K.; Kumar, A.; Foster, T. C. Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II. J. Neurosci., 2010, 30 (5), 1914-24.
61. Taffe, M. A.; Weed, M. R.; Gutierrez, T.; Davis, S. A.; Gold, L. H. Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys. Psychopharmacology, (Berl)., 2002, 160 (3), 253-62.
62. Procter, A. W.; Wong, E. H.; Stratmann, G. C.; Lowe, S. L.; Bowen, D. M. Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease. J. Neurochem., 1989, 53 (3), 698-704.
63. Schaeffer, E. L.; Gattaz, W. F. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl)., 2008, 198 (1), 1-27.
64. Jiang, H.; Jia, J. Association between NR2B subunit gene (GRIN2B) promoter polymorphisms and sporadic Alzheimer's disease in the North Chinese population. Neurosci. Lett., 2009, 450 (3), 356-60.
65. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; Nairn, A. C.; Salter, M. W.; Lombroso, P. J.; Gouras, G. K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci., 2005, 8 (8), 1051-8.
66. Auffret, A.; Gautheron, V.; Repici, M.; Kraftsik, R.; Mount, H. T.; Mariani, J.; Rovira, C. Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. J. Neurosci., 2009, 29 (32), 10144-52.
67. Auffret, A.; Gautheron, V.; Mattson, M. P.; Mariani, J.; Rovira, C. Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice. J. Alzheimer's Dis., 2010, 19 (3), 1021-33.
68. Mishizen-Eberz, A. J.; Rissman, R. A.; Carter, T. L.; Ikonomovic, M. D.; Wolfe, B. B.; Armstrong, D. M. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol. Dis., 2004, 15 (1), 80-92.
69. Martinez, M.; Frank, A.; Diez-Tejedor, E.; Hernanz, A. Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. J. Neural Transm. Park. Dis. Dement. Sect., 1993, 6 (1), 1-9.
70. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Okada, S.; Komatsu, N.; Okamura, N.; Koike, K.; Koizumi, H.; Kumakiri, C.; Imai, K.; Iyo, M. Possible role of D-serine in the pathophysiology of Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28 (2), 385-8.
71. Lowe, S. L.; Bowen, D. M. Glutamic acid concentration in brains of patients with Alzheimer's disease. Biochem. Soc. Trans., 1990, 18 (3), 443-4.
72. Deutsch, J. A. The cholinergic synapse and the site of memory. Science, 1971, 174 (4011), 788-94.
73. Blokland, A., Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Brain Res. Rev., 1995, 21 (3), 285-300.
74. Patel, S.; Tariot, P. N. Pharmacologic models of Alzheimer's disease. Psychiatr. Clin. North Am. 1991, 14 (2), 287-308.
75. Katzman, R.; Brown, T.; Fuld, P.; Thal, L.; Davies, P.; Terry, R. Significance of neurotransmitter abnormalities in Alzheimer's disease. Res. Publ. Assoc. Res. Nerv. Ment. Dis., 1986, 64, 279-86.
76. Bierer, L. M.; Haroutunian, V.; Gabriel, S.; Knott, P. J.; Carlin, L. S.; Purohit, D. P.; Perl, D. P.; Schmeidler, J.; Kanof, P.; Davis, K. L. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem., 1995, 64 (2), 749-60.
77. Lleo, A.; Greenberg, S. M.; Growdon, J. H. Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med., 2006, 57, 513-33.
78. Markram, H.; Segal, M. The inositol 1,4,5-trisphosphate pathway mediates cholinergic potentiation of rat hippocampal neuronal responses to NMDA. J. Physiol., 1992, 447, 513-33.
79. Navakkode, S.; Korte, M. Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage. Hippocampus, 2012, 22 (2), 335-46.
80. Flores-Hernandez, J.; Salgado, H.; De La Rosa, V.; Avila-Ruiz, T.; Torres-Ramirez, O.; Lopez-Lopez, G.; Atzori, M. Cholinergic direct inhibition of N-methyl-D aspartate receptor-mediated currents in the rat neocortex. Synapse, 2009, 63 (4), 308-18.
81. Shen, H.; Kihara, T.; Hongo, H.; Wu, X.; Kem, W. R.; Shimohama, S.; Akaike, A.; Niidome, T.; Sugimoto, H. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br. J. Pharmacol., 2010, 161 (1), 127-39.
82. Chen, G.; Chen, P.; Tan, H.; Ma, D.; Dou, F.; Feng, J.; Yan, Z. Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease. Neurobiol. Aging, 2008, 29 (12), 1795-804.
83. Marcello, E.; Gardoni, F.; Mauceri, D.; Romorini, S.; Jeromin, A.; Epis, R.; Borroni, B.; Cattabeni, F.; Sala, C.; Padovani, A.; Di Luca, M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J. Neurosci., 2007, 27 (7), 1682-91.
84. Hoey, S. E.; Williams, R. J.; Perkinton, M. S. Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J. Neurosci., 2009, 29 (14), 4442-60.
85. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci., 2007, 27 (11), 2866-75.
86. Yamin, G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J. Neurosci. Res., 2009, 87 (8), 1729-36.
87. Cisse, M.; Halabisky, B.; Harris, J.; Devidze, N.; Dubal, D. B.; Sun, B.; Orr, A.; Lotz, G.; Kim, D. H.; Hamto, P.; Ho, K.; Yu, G. Q.; Mucke, L. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature, 2011, 469 (7328), 47-52.
88. Kamenetz, F.; Tomita, T.; Hsieh, H.; Seabrook, G.; Borchelt, D.; Iwatsubo, T.; Sisodia, S.; Malinow, R. APP processing and synaptic function. Neuron, 2003, 37 (6), 925-37.
89. Goto, Y.; Niidome, T.; Akaike, A.; Kihara, T.; Sugimoto, H. Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. Biochem. Biophys. Res. Commun., 2006, 351 (1), 259-65.
90. Kurup, P.; Zhang, Y.; Xu, J.; Venkitaramani, D. V.; Haroutunian, V.; Greengard, P.; Nairn, A. C.; Lombroso, P. J. A-Mediated NMDA Receptor Endocytosis in Alzheimer's Disease Involves Ubiquitination of the Tyrosine Phosphatase STEP61. J. Neurosci., 2010, 30 (17), 5948-5957.
91. Chen, Q. S.; Wei, W. Z.; Shimahara, T.; Xie, C. W. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem., 2002, 77 (3), 354-71.
92. Zhao, D.; Watson, J. B.; Xie, C. W. Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J. Neurophysiol., 2004, 92 (5), 2853-8.
93. Knobloch, M.; Farinelli, M.; Konietzko, U.; Nitsch, R. M.; Mansuy, I. M. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J. Neurosci., 2007, 27 (29), 7648-53.
94. Chen, Y.; Durakoglugil, M. S.; Xian, X.; Herz, J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl. Acad. Sci. U. S. A., 2010, 107 (26), 12011-6.
95. Chen, H. S.; Lipton, S. A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem., 2006, 97 (6), 1611-26.
96. Morris, R. G.; Anderson, E.; Lynch, G. S.; Baudry, M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature, 1986, 319 (6056), 774-6.
97. Matsuoka, N.; Aigner, T. G. The glycine/NMDA receptor antagonist HA-966 impairs visual recognition memory in rhesus monkeys. Brain Res., 1996, 731 (1-2), 72-8.
98. Rowland, L. M.; Astur, R. S.; Jung, R. E.; Bustillo, J. R.; Lauriello, J.; Yeo, R. A. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology, 2005, 30 (3), 633-9.
99. van der Staay, F. J.; Rutten, K.; Erb, C.; Blokland, A. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behav. Brain Res., 2011, 220 (1), 215-29.
100. Kos, T.; Nikiforuk, A.; Rafa, D.; Popik, P. The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice. Psychopharmacology (Berl)., 2011, 214 (4), 911-21.
101. Reisberg, B.; Doody, R.; Stöffler, A.; Schmitt, F.; Ferris, S.; Möbius, H. J.; Group., t. M. S. Memantine in Moderate-to-Severe Alzheimer Disease. N. Engl. J. Med., 2003, 348, 1333-41.
102. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol., 2003, 2 (9), 539-47.
103. Pallàs, M.; Camins, A. Molecular and Biochemical Features in Alzheimer disease. Curr. Pharm. Des., 2006, 12, 4389-408.
104. Gardoni, F.; Di Luca, M. New targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol., 2006, 545 (1), 2-10.
105. More, L.; Gravius, A.; Nagel, J.; Valastro, B.; Greco, S.; Danysz, W. Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Behav. Pharmacol., 2008, 19 (7), 724-34.
106. Coyle, J. T.; Puttfarcken, P. Oxidative stress, glutamate, and neurodegenerative disorders. Science, 1993, 262 (5134), 689-95.
107. Lin, C. H.; Lane, H. Y.; Tsai, G. E. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol. Biochem. Behav., 2012, 100 (4), 665-77.
108. Ballard, T. M.; Pauly-Evers, M.; Higgins, G. A.; Ouagazzal, A. M.; Mutel, V.; Borroni, E.; Kemp, J. A.; Bluethmann, H.; Kew, J. N. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug resistant nonhabituating hyperactivity. J. Neurosci., 2002, 22 (15), 6713-23.
109. Kew, J. N.; Koester, A.; Moreau, J. L.; Jenck, F.; Ouagazzal, A. M.; Mutel, V.; Richards, J. G.; Trube, G.; Fischer, G.; Montkowski, A.; Hundt, W.; Reinscheid, R. K.; Pauly-Evers, M.; Kemp, J. A.; Bluethmann, H. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J. Neurosci., 2000, 20 (11), 4037-49.
110. Flood, J. F.; Morley, J. E.; Lanthorn, T. H. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur. J. Pharmacol., 1992, 221 (2-3), 249-54.
111. Schuster, G. M.; Schmidt, W. J. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur. J. Pharmacol., 1992, 224 (1), 97-8.
112. Thompson, L. T.; Moskal, J. R.; Disterhoft, J. F. Hippocampus dependent learning facilitated by a monoclonal antibody or Dcycloserine. Nature 1992, 359 (6396), 638-41.
113. Randolph, C.; Roberts, J. W.; Tierney, M. C.; Bravi, D.; Mouradian, M. M.; Chase, T. N. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 1994, 8 (3), 198-205.
114. Tsai, G. E.; Falk, W. E.; Gunther, J. A preliminary study of Dcycloserine treatment in Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci., 1998, 10 (2), 224-6.
115. Tsai, G. E.; Falk, W. E.; Gunther, J.; Coyle, J. T. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am. J. Psychiatry, 1999, 156 (3), 467-9.
116. Fakouhi, T. D.; Jhee, S. S.; Sramek, J. J.; Benes, C.; Schwartz, P.; Hantsburger, G.; Herting, R.; Swabb, E. A.; Cutler, N. R. Evaluation of cycloserine in the treatment of Alzheimer's disease. J. Geriatr. Psychiatry Neurol., 1995, 8 (4), 226-30.
117. Mohr, E.; Knott, V.; Sampson, M.; Wesnes, K.; Herting, R.; Mendis, T. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clin. Neuropharmacol., 1995, 18 (1), 28-38.
118. Moskal, J. R.; Kuo, A. G.; Weiss, C.; Wood, P. L.; O'Connor Hanson, A.; Kelso, S.; Harris, R. B.; Disterhoft, J. F. GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-Daspartate receptor modulator. Neuropharmacology, 2005, 49 (7), 1077-87.
119. Burgdorf, J.; Zhang, X. L.; Weiss, C.; Matthews, E.; Disterhoft, J. F.; Stanton, P. K.; Moskal, J. R. The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol. Aging, 2011, 32 (4), 698-706.
120. Finkel, S. Behavioral and psychologic symptoms of dementia. Clin. Geriatr. Med., 2003, 19 (4), 799-824.
121. Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br. J. Psychiatry, 1990, 157, 72-6, 92-4.
122. Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception. Br. J. Psychiatry, 1990, 157, 76-81, 92-4.
123. Burns, A.; Jacoby, R.; Levy, R. Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood. Br. J. Psychiatry, 1990, 157, 81-6, 92-4.
124. O'Brien, J. Behavioral symptoms in vascular cognitive impairment and vascular dementia. Int. Psychogeriatr., 2003, 15 Suppl 1, 133-8.
125. Kim, J. M.; Lyons, D.; Shin, I. S.; Yoon, J. S. Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable? Hum. Psychopharmacol., 2003, 18 (3), 215-20.
126. Savva, G. M.; Zaccai, J.; Matthews, F. E.; Davidson, J. E.; McKeith, I.; Brayne, C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br. J. Psychiatry, 2009, 194 (3), 212-9.
127. Paulsen, J. S.; Salmon, D. P.; Thal, L. J.; Romero, R.; Weisstein Jenkins, C.; Galasko, D.; Hofstetter, C. R.; Thomas, R.; Grant, I.; Jeste, D. V. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology, 2000, 54 (10), 1965-71.
128. Devanand, D. P. Behavioral complications and their treatment in Alzheimer's disease. Geriatrics, 1997, 52 Suppl 2, S37-9.
129. Steinberg, M.; Shao, H.; Zandi, P.; Lyketsos, C. G.; Welsh Bohmer, K. A.; Norton, M. C.; Breitner, J. C.; Steffens, D. C.; Tschanz, J. T. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int. J. Geriatr. Psychiatry, 2008, 23 (2), 170-7.
130. Thompson, C.; Brodaty, H.; Trollor, J.; Sachdev, P. Behavioral and psychological symptoms associated with dementia subtype and severity. Int. Psychogeriatr., 2010, 22 (2), 300-5.
131. Borroni, B.; Agosti, C.; Padovani, A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch. Gerontol. Geriatr., 2008, 46 (1), 101-6.
132. Hersch, E. C.; Falzgraf, S. Management of the behavioral and psychological symptoms of dementia. Clin. Interven. Aging, 2007, 2 (4), 611-21.
133. Shah, A.; Dalvi, M.; Thompson, T. Is there a need to study behavioral and psychological signs and symptoms of dementia across cultures? Int. Psychogeriatr., 2005, 17 (3), 513-8.
134. Bourgeois, M. S.; Schulz, R.; Burgio, L. Interventions for caregivers of patients with Alzheimer's disease: a review and analysis of content, process, and outcomes. Int. J. Aging Hum. Dev., 1996, 43 (1), 35-92.
135. Deimling, G. T.; Bass, D. M. Symptoms of mental impairment among elderly adults and their effects on family caregivers. J. Gerontol., 1986, 41 (6), 778-84.
136. Rabins, P. V.; Mace, N. L.; Lucas, M. J. The impact of dementia on the family. JAMA, 1982, 248 (3), 333-5.
137. Draper, B.; Snowdon, J.; Meares, S.; Turner, J.; Gonski, P.; McMinn, B.; McIntosh, H.; Latham, L.; Draper, D.; Luscombe, G. Case-controlled study of nursing home residents referred for treatment of vocally disruptive behavior. Int. Psychogeriatr., 2000, 12 (3), 333-44.
138. Rodney, V. Nurse stress associated with aggression in people with dementia: its relationship to hardiness, cognitive appraisal and coping. J. Adv. Nurs., 2000, 31 (1), 172-80.
139. Sink, K. M.; Holden, K. F.; Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA, 2005, 293 (5), 596-608.
140. Lee, P. E.; Gill, S. S.; Freedman, M.; Bronskill, S. E.; Hillmer, M. P.; Rochon, P. A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ, 2004, 329 (7457), 75.
141. Ballard, C.; Corbett, A.; Chitramohan, R.; Aarsland, D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr. Opin. Psychiatry, 2009, 22 (6), 532-40.
142. Schneider, L. S.; Tariot, P. N.; Dagerman, K. S.; Davis, S. M.; Hsiao, J. K.; Ismail, M. S.; Lebowitz, B. D.; Lyketsos, C. G.; Ryan, J. M.; Stroup, T. S.; Sultzer, D. L.; Weintraub, D.; Lieberman, J. A. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med., 2006, 355 (15), 1525-38.
143. Vigen, C. L.; Mack, W. J.; Keefe, R. S.; Sano, M.; Sultzer, D. L.; Stroup, T. S.; Dagerman, K. S.; Hsiao, J. K.; Lebowitz, B. D.; Lyketsos, C. G.; Tariot, P. N.; Zheng, L.; Schneider, L. S. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am. J. Psychiatry, 2011, 168 (8), 831-9.
144. Food Drug Administration. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. FDA Public Health Advisory. 2005. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. [Accessed on: 30th December, 2008].
145. Schneider, L. S.; Dagerman, K. S.; Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005, 294 (15), 1934-43.
146. Wang, P. S.; Schneeweiss, S.; Avorn, J.; Fischer, M. A.; Mogun, H.; Solomon, D. H.; Brookhart, M. A. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med., 2005, 353 (22), 2335-41.
147. Ballard, C.; Waite, J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst. Rev., 2006, (1), CD003476.
148. Weiner, M. F.; Martin-Cook, K.; Foster, B. M.; Saine, K.; Fontaine, C. S.; Svetlik, D. A. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J. Clin. Psychiatry, 2000, 61 (7), 487-92.
149. Gauthier, S.; Feldman, H.; Hecker, J.; Vellas, B.; Ames, D.; Subbiah, P.; Whalen, E.; Emir, B. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int. Psychogeriatr., 2002, 14 (4), 389-404.
150. Paleacu, D.; Mazeh, D.; Mirecki, I.; Even, M.; Barak, Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin. Neuropharmacol., 2002, 25 (6), 313-7.
151. Bergman, J.; Brettholz, I.; Shneidman, M.; Lerner, V. Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type. Clin. Neuropharmacol., 2003, 26 (2), 88-92.
152. Holmes, C.; Wilkinson, D.; Dean, C.; Vethanayagam, S.; Olivieri, S.; Langley, A.; Pandita-Gunawardena, N. D.; Hogg, F.; Clare, C.; Damms, J. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology, 2004, 63 (2), 214-9.
153. Cummings, J. L.; McRae, T.; Zhang, R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry, 2006, 14 (7), 605-12.
154. Howard, R. J.; Juszczak, E.; Ballard, C. G.; Bentham, P.; Brown, R. G.; Bullock, R.; Burns, A. S.; Holmes, C.; Jacoby, R.; Johnson, T.; Knapp, M.; Lindesay, J.; O'Brien, J. T.; Wilcock, G.; Katona, C.; Jones, R. W.; DeCesare, J.; Rodger, M. Donepezil for the treatment of agitation in Alzheimer's disease. N. Engl. J. Med., 2007, 357 (14), 1382-92.
155. Pelosi, A. Donepezil is no more effective than placebo for agitation in people with Alzheimer's disease. Evid. Based Ment. Health, 2008, 11 (3), 84.
156. Reekum, R. Donepezil was no better than placebo for agitation in patients with Alzheimer disease. ACP J. Club, 2008, 148 (2), 33.
157. Carrasco, M. M.; Aguera, L.; Gil, P.; Morinigo, A.; Leon, T. Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2011, 25 (4), 333-40.
158. Tariot, P. N.; Solomon, P. R.; Morris, J. C.; Kershaw, P.; Lilienfeld, S.; Ding, C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 2000, 54 (12), 2269-76.
159. Rockwood, K.; Mintzer, J.; Truyen, L.; Wessel, T.; Wilkinson, D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J. Neurol. Neurosurg. Psychiatry, 2001, 71 (5), 589-95.
160. Monsch, A. U.; Giannakopoulos, P. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Curr. Med. Res. Opin., 2004, 20 (6), 931-8.
161. Herrmann, N.; Rabheru, K.; Wang, J.; Binder, C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am. J. Geriatr. Psychiatry, 2005, 13 (6), 527-34.
162. Finkel, S. I. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Ther., 2004, 26 (7), 980-90.
163. Cummings, J. L.; Koumaras, B.; Chen, M.; Mirski, D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am. J. Geriatric Pharmacother., 2005, 3 (3), 137-48.
164. Edwards, K.; Koumaras, B.; Chen, M.; Gunay, I.; Mirski, D. Long term effects of rivastigmine treatment on the need for psychotropic medications in nursing home patients with Alzheimer's disease: results of a 52-week open-label study. Clin. Drug Investig., 2005, 25 (8), 507-15.
165. Gauthier, S.; Juby, A.; Rehel, B.; Schecter, R. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int. J. Clin. Pract., 2007, 61 (6), 886-95.
166. Kaufer, D. I.; Cummings, J. L.; Christine, D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J. Geriatr. Psychiatry Neurol., 1996, 9 (1), 1-6.
167. Trinh, N. H.; Hoblyn, J.; Mohanty, S.; Yaffe, K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta analysis. JAMA, 2003, 289 (2), 210-6.
168. Madhusoodanan, S.; Shah, P.; Brenner, R.; Gupta, S. Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach? CNS Drugs, 2007, 21 (2), 101-15.
169. Konovalov, S.; Muralee, S.; Tampi, R. R. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int. Psychogeriatr., 2008, 20 (2), 293-308.
170. Borroni, B.; Grassi, M.; Agosti, C.; Costanzi, C.; Archetti, S.; Franzoni, S.; Caltagirone, C.; Di Luca, M.; Caimi, L.; Padovani, A. Genetic correlates of behavioral endophenotypes in Alzheimer disease: role of COMT, 5-HTTLPR and APOE polymorphisms. Neurobiol. Aging, 2006, 27 (11), 1595-603.
171. Lanari, A.; Amenta, F.; Silvestrelli, G.; Tomassoni, D.; Parnetti, L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev., 2006, 127 (2), 158-65.
172. Garcia-Alloza, M.; Gil-Bea, F. J.; Diez-Ariza, M.; Chen, C. P.; Francis, P. T.; Lasheras, B.; Ramirez, M. J. Cholinergic serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia, 2005, 43 (3), 442-9.
173. Cummings, J. L.; Kaufer, D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology, 1996, 47 (4), 876-83.
174. Lanctot, K. L.; Herrmann, N.; Mazzotta, P. Role of serotonin in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci., 2001, 13 (1), 5-21.
175. Pritchard, A. L.; Harris, J.; Pritchard, C. W.; Coates, J.; Haque, S.; Holder, R.; Bentham, P.; Lendon, C. L. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease. Neurobiol. Aging, 2008, 29 (3), 341-7.
176. Ueki, A.; Ueno, H.; Sato, N.; Shinjo, H.; Morita, Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease. J. Alzheimer's Dis., 2007, 12 (3), 245-53.
177. Pritchard, A. L.; Pritchard, C. W.; Bentham, P.; Lendon, C. L. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement. Geriatr. Cogn. Disord., 2007, 24 (3), 201-6.
178. Proitsi, P.; Lupton, M. K.; Reeves, S. J.; Hamilton, G.; Archer, N.; Martin, B. M.; Iyegbe, C.; Hollingworth, P.; Lawlor, B.; Gill, M.; Brayne, C.; Rubinsztein, D. C.; Owen, M. J.; Williams, J.; Lovestone, S.; Powell, J. F. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol. Aging, 2012, 33 (4), 791-803.
179. Mitchell, R. A.; Herrmann, N.; Lanctot, K. L. The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci. Ther., 2011, 17 (5), 411-27.
180. Tanaka, Y.; Meguro, K.; Yamaguchi, S.; Ishii, H.; Watanuki, S.; Funaki, Y.; Yamaguchi, K.; Yamadori, A.; Iwata, R.; Itoh, M. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med., 2003, 17 (7), 567-73.
181. Sato, N.; Ueki, A.; Ueno, H.; Shinjo, H.; Morita, Y. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type. J. Alzheimer's Dis., 2009, 17 (2), 441-8.
182. Herrmann, N.; Lanctot, K. L.; Khan, L. R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci., 2004, 16 (3), 261-76.
183. Garcia-Alloza, M.; Tsang, S. W.; Gil-Bea, F. J.; Francis, P. T.; Lai, M. K.; Marcos, B.; Chen, C. P.; Ramirez, M. J. Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. Neurobiol. Aging, 2006, 27 (8), 1110-7.
184. Lanctot, K. L.; Herrmann, N.; Rothenburg, L.; Eryavec, G. Behavioral correlates of GABAergic disruption in Alzheimer's disease. Int. Psychogeriatr., 2007, 19 (1), 151-8.
185. Siegel, A.; Schubert, K. Neurotransmitters regulating feline aggressive behavior. Rev. Neurosci., 1995, 6 (1), 47-61.
186. Peeters, B. W.; Van Rijn, C. M.; Van Luijtelaar, E. L.; Coenen, A. M. Antiepileptic and behavioural actions of MK-801 in an animal model of spontaneous absence epilepsy. Epilepsy Res., 1989, 3 (2), 178-81.
187. Wedzony, K.; Fijal, K.; Mackowiak, M.; Chocyk, A.; Zajaczkowski, W. Impact of postnatal blockade of N-methyl-Daspartate receptors on rat behavior: a search for a new developmental model of schizophrenia. Neuroscience, 2008, 153 (4), 1370-9.
188. Francis, P. T. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr. Mol. Pharmacol., 2009, 2 (1), 77-82.
189. Wang, D.; Noda, Y.; Tsunekawa, H.; Zhou, Y.; Miyazaki, M.; Senzaki, K.; Nabeshima, T. Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety. Behav. Brain Res., 2007, 178 (2), 262-73.
190. Cryan, J. F.; O'Leary, O. F. Neuroscience. A glutamate pathway to faster-acting antidepressants? Science, 2010, 329 (5994), 913-4.
191. Li, N.; Lee, B.; Liu, R. J.; Banasr, M.; Dwyer, J. M.; Iwata, M.; Li, X. Y.; Aghajanian, G.; Duman, R. S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010, 329 (5994), 959-64.
192. Barkus, C.; McHugh, S. B.; Sprengel, R.; Seeburg, P. H.; Rawlins, J. N.; Bannerman, D. M. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur. J. Pharmacol., 2010, 626 (1), 49-56.
193. Labrie, V.; Clapcote, S. J.; Roder, J. C. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol. Biochem. Behav., 2009, 91 (4), 610-20.
194. Richardson, R.; Ledgerwood, L.; Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn. Mem., 2004, 11 (5), 510-6.
195. Bacanu, S.-A.; Devlin, B.; Chowdari, K. V.; DeKosky, S. T.; Nimgaonkar, V. L.; Sweet, R. A. Linkage analysis of Alzheimer disease with psychosis. Neurology, 2002, 59, 118-20.
196. Ellison, G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Brain Res. Rev., 1995, 20 (2), 250-67.
197. Di Maria, E.; Bonvicini, C.; Bonomini, C.; Alberici, A.; Zanetti, O.; Gennarelli, M. Genetic variation in the G720/G30 gene locus (DAOA) influences the occurrence of psychotic symptoms in patients with Alzheimer's disease. J. Alzheimer's Dis., 2009, 18 (4), 953-60.
198. Chumakov, I.; Blumenfeld, M.; Guerassimenko, O.; Cavarec, L.; Palicio, M.; Abderrahim, H.; Bougueleret, L.; Barry, C.; Tanaka, H.; La Rosa, P.; Puech, A.; Tahri, N.; Cohen-Akenine, A.; Delabrosse, S.; Lissarrague, S.; Picard, F. P.; Maurice, K.; Essioux, L.; Millasseau, P.; Grel, P.; Debailleul, V.; Simon, A. M.; Caterina, D.; Dufaure, I.; Malekzadeh, K.; Belova, M.; Luan, J. J.; Bouillot, M.; Sambucy, J. L.; Primas, G.; Saumier, M.; Boubkiri, N.; Martin Saumier, S.; Nasroune, M.; Peixoto, H.; Delaye, A.; Pinchot, V.; Bastucci, M.; Guillou, S.; Chevillon, M.; Sainz-Fuertes, R.; Meguenni, S.; Aurich-Costa, J.; Cherif, D.; Gimalac, A.; Van Duijn, C.; Gauvreau, D.; Ouellette, G.; Fortier, I.; Raelson, J.; Sherbatich, T.; Riazanskaia, N.; Rogaev, E.; Raeymaekers, P.; Aerssens, J.; Konings, F.; Luyten, W.; Macciardi, F.; Sham, P. C.; Straub, R. E.; Weinberger, D. R.; Cohen, N.; Cohen, D. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A., 2002, 99 (21), 13675-80.
199. Li, Y. C.; Xi, D.; Roman, J.; Huang, Y. Q.; Gao, W. J. Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J. Neurosci., 2009, 29 (49), 15551-63.
200. Chan, M. H.; Chiu, P. H.; Lin, C. Y.; Chen, H. H. Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine. Schizophr. Res., 2012, 136 (1-3), 96-103.
201. Tsang, S. W.; Vinters, H. V.; Cummings, J. L.; Wong, P. T.; Chen, C. P.; Lai, M. K. Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol. Aging, 2008, 29 (10), 1524-32.
202. Tariot, P. N.; Farlow, M. R.; Grossberg, G. T.; Graham, S. M.; McDonald, S.; Gergel, I.; Group, t. M. S. Memantine treatment in patients with moderate to severe alzheimer disease already receiving donepezil. A Randomized Controlled Trial. JAMA, 2004, 291.
203. Cummings, J. L.; Schneider, E.; Tariot, P. N.; Graham, S. M. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 2006, 67 (1), 57-63.
204. van Dyck, C. H.; Tariot, P. N.; Meyers, B.; Malca, R. E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2007, 21 (2), 136-43.
205. Cretu, O.; Szalontay, A. S.; Chirita, R.; Chirita, V. Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil. Rev. Med. Chir. Soc. Med. Nat. Iasi, 2008, 112 (3), 641-5.
206. Gauthier, S.; Loft, H.; Cummings, J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int. J. Geriatr. Psychiatry, 2008, 23 (5), 537-45.
207. Wilcock, G. K.; Ballard, C. G.; Cooper, J. A.; Loft, H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J. Clin. Psychiatry, 2008, 69 (3), 341-8.
208. Schmidt, R.; Baumhackl, U.; Berek, K.; Brucke, T.; Kapeller, P.; Lechner, A.; Rainer, M.; Stogerer, E. M. [Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria]. Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2010, 24 (2), 125-31.
209. Herrmann, N.; Cappell, J.; Eryavec, G. M.; Lanctot, K. L. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs, 2011, 25 (5), 425-33.
210. Clerici, F.; Vanacore, N.; Elia, A.; Spila-Alegiani, S.; Pomati, S.; Da Cas, R.; Raschetti, R.; Mariani, C. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurolo Sci: Official Journal Ital Neurol Soc Ital Soc Clin Neurophysiol., 2012, 33 (1), 23-31.
211. Fox, C.; Crugel, M.; Maidment, I.; Auestad, B. H.; Coulton, S.; Treloar, A.; Ballard, C.; Boustani, M.; Katona, C.; Livingston, G., Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PloS One, 2012, 7 (5), e35185.
212. Gauthier, S.; Wirth, Y.; Mobius, H. J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry, 2005, 20 (5), 459-64.
213. Tsai, G.; Lane, H. Y.; Yang, P.; Chong, M. Y.; Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry, 2004, 55 (5), 452-6.
214. Lane, H. Y.; Chang, Y. C.; Liu, Y. C.; Chiu, C. C.; Tsai, G. E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry, 2005, 62 (11), 1196-204.
215. Lane, H. Y.; Huang, C. L.; Wu, P. L.; Liu, Y. C.; Chang, Y. C.; Lin, P. Y.; Chen, P. W.; Tsai, G. Glycine transporter I inhibitor, Nmethylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry, 2006, 60 (6), 645-9.
216. Lane, H. Y.; Liu, Y. C.; Huang, C. L.; Chang, Y. C.; Liau, C. H.; Perng, C. H.; Tsai, G. E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol. Psychiatry, 2008, 63 (1), 9-12.
217. Lane, H. Y.; Lin, C. H.; Huang, Y. J.; Liao, C. H.; Chang, Y. C.; Tsai, G. E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol., 2010, 13 (4), 451-60.
218. Heresco-Levy, U.; Javitt, D. C.; Ermilov, M.; Mordel, C.; Silipo, G.; Lichtenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry, 1999, 56 (1), 29-36.
219. Javitt, D. C.; Silipo, G.; Cienfuegos, A.; Shelley, A. M.; Bark, N.; Park, M.; Lindenmayer, J. P.; Suckow, R.; Zukin, S. R. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol., 2001, 4 (4), 385-91.
220. Heresco-Levy, U.; Javitt, D. C.; Ebstein, R.; Vass, A.; Lichtenberg, P.; Bar, G.; Catinari, S.; Ermilov, M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment refractory schizophrenia. Biol. Psychiatry, 2005, 57 (6), 577-85.
221. Huang, C. C.; Wei, I. H.; Huang, C. L.; Chen, K. T.; Tsai, M. H.; Tsai, P.; Huang K. H.; Chang, Y. C.; Lane, H. Y.; Tsai, G. E. Inhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression. Biol Psychiatry, accepted.
222. Strick, C. A.; Li, C.; Scott, L.; Harvey, B.; Hajos, M.; Steyn, S. J.; Piotrowski, M. A.; James, L. C.; Downs, J. T.; Rago, B.; Becker, S. L.; El-Kattan, A.; Xu, Y.; Ganong, A. H.; Tingley, F. D., 3rd; Ramirez, A. D.; Seymour, P. A.; Guanowsky, V.; Majchrzak, M. J.; Fox, C. B.; Schmidt, C. J.; Duplantier, A. J. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Neuropharmacology, 2011, 61 (5-6), 1001-15.